the patient that might otherwise go unrecognized. Previous studies suggest reduced QOL in some patients with adrenal disease even when biochemical cure is possible. There is no single approach to define, conceptualize or measure QOL. For this review, QOL will refer to any measure that elicits the patient experience.
There is growing interest in QOL evaluation in patients with adrenal disease. However, the lack of clearly defined QOL concepts and potential confounders pose challenges in the interpretation of the data and its validity. To our knowledge, this is the first systematic review of QOL in adrenal disease. The objectives were to describe how QOL is defined and measured in adrenal disease, critically appraise the use of QOL tools, discuss the clinical implications of these findings and provide direction for further research in this field.
| QOL concepts
The World Health Organization defines quality of life (QOL) as "an individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns". 1 Whereas QOL encompasses all aspects of human life (including health, physical functioning, social functioning, housing, income, values, culture, spirituality, life satisfaction), health-related quality of life (HRQOL)
focuses on the effects of illness and treatment on QOL. 2 The terms "domains" or "dimensions" refer to areas of experience of behaviour being measured as outcomes by researchers. 3 The fundamental principle of QOL research is that the patient is the best source of information regarding his or her own experience. 4 Proxy reports are less reliable. Clinicians tend to underestimate the impact of disease, whereas caregivers may overestimate functional limitations. 3 The "minimum important difference" is the smallest change in QOL scores that is perceived by patients as beneficial or harmful and would lead to the clinician to consider a change in treatment. 5 
| QOL evaluation
Qualitative methods involve semistructured interviews. These may provide data unobtainable by scoring systems, by directing our attention to aspects of QOL more pertinent to that individual. The limitations are that it requires a skilled interviewer, is time-consuming, often small sample size, and data cannot be used for monitoring or comparison with other study populations.
Quantitative methods involve administering validated questionnaires. Generic questionnaires encompass physical, mental and social health dimensions common to a wide range of conditions and allow comparison of QOL burden or treatment benefit across disease or populations. Disease-specific questionnaires aim to highlight the particular concerns of patients with the disease of interest.
Domain-specific questionnaires are used when emphasis is required from a particular domain to address the study hypothesis. Multiple tools provide more comprehensive data. However, this needs to be weighed against patient and investigator burden. required from a particular domain to address the study hypothesis.
| Development and validation of QOL tools
The process begins with a literature search to identify HRQOL issues followed by interviews with patients and experts in the field.
Patient responses are used to create items for the questionnaire.
Pretesting is performed in a cohort of patients to guide item reduction before field testing. 9, 10 To ensure that claims of QOL benefit in clinical trials are made using tools that are methodologically sound, QOL tools are required to comply with development and testing standards as documented in an instrument dossier, according to guidance provided by regulatory agencies. 9, 11 Quality of life questionnaires are required to fulfil eight criteria 12, 13 (Table 1 ). However, it should be noted that these criteria are not consistently defined in the literature. Calculation of Cronbach's alpha is frequently selected for reliability testing or internal consistency to describe the extent to which the QOL tool is free from random error. 
| RE SULTS

| Study selection and participants
A total of 117 studies were included in the review ( Figure 1 ). The initial search identified 2494 studies, and a further two studies were identified from alternative sources such as abstracts from endocrine meetings. Title and abstract were screened for 2496 records. If QOL data were not displayed in the paper, the Appendix S1 was screened.
Most studies were excluded as they related to steroid use in other chronic illnesses, or because QOL data were not shown or were not sufficiently reported.
The study characteristics, rationale for QOL evaluation, type of QOL tools used and the key findings for each study, with studies grouped by type of adrenal disease, are contained with the Appendix S1. The review comprised 80% observational studies and 20% ran- The publications included information about 13 717 adults with confirmed adrenal disease. Overall QOL was reduced across the spectrum of adrenal disease (Table 3 ). However, QOL was more frequently evaluated in patients with chronic adrenal insufficiency (45 studies) or Cushing's syndrome (42 studies). Patients with congenital adrenal hyperplasia (CAH; 20 studies) were considered separately due to issues relating to androgen excess in addition to adrenal insufficiency. There were far fewer studies evaluating QOL in patients with primary aldosteronism (8 studies) and very limited data concerning QOL patients presenting with an adrenal mass (5 studies) or paraganglioma (3 studies). No studies were identified focusing primarily on QOL and mineralocorticoid deficiency or phaeochromocytoma.
| Defining QOL in patients with adrenal disease
The vast majority (96%) of studies did not define QOL. 
| Measuring QOL in patients with adrenal disease
In interventional studies, QOL tools were used to evaluate medical interventions (71%), surgical interventions (24%) or both (5%).
In noninterventional studies, QOL instruments were used to assess disease impact (44%), correlate QOL findings with other parameters (such as biochemical findings, genotype or symptom burden) (23%), explore factors which may influence QOL (16%), develop QOL instruments (16%) and compare QOL with other conditions (1%).
Quantitative assessments were performed in all studies, with only 5% combining this with a qualitative approach. The most common approach was to combine generic and domain-specific tools, although disease-specific tools are increasingly being used (and are only available) to evaluate patients with Cushing's syndrome and
Addison's disease.
TA B L E 3
Quality of life across the spectrum of adrenal disease. Study details and references in Appendix S1
Adrenal disease Key findings
Cushing's syndrome • QOL is severely reduced in active Cushing's syndrome • QOL improves with treatment but remains significantly reduced compared to the general population despite long-term remission The majority of studies cited validity of the QOL tools used. A total of 92 different tools were used to evaluate aspects of QOL in this review, with multiple questionnaires used in 70% of studies.
Overall, the SF-36 was the most widely used tool. Reporting quality was highly variable as rated by adherence to ten features of the CONSORT-PRO guidelines (Figure 2 ). Overall, 78% of studies adhered to at least half of the recommendations, and 59% of the guidance was adhered to across the studies (Figure 3 ). Deficiencies include not disclosing the extent of missing data or discussing how this was dealt with statistically.
| QOL in Cushing syndrome
Quality of life is severely reduced in active Cushing's syndrome, improving with treatment but remaining significantly impaired compared with the general population despite long-term remission. This reduction was a consistent finding across all the studies, irrespective of aetiology, the presence of concurrent hormonal deficiencies, treatment strategies, the severity of hypercortisolism and time elapsed since cure.
20,21
Quality of life was reduced in all forms of hypothalamic-pituitaryadrenal dysregulation, but most profoundly reduced in patients with
Cushing's syndrome with active hypercortisolemia. [20] [21] [22] Clinical recovery is slower than biochemical recovery, with patient-defined recovery taking longer than physician-defined recovery and psychiatric features less likely to improve compared with other Cushing-related comorbidities. 23, 24 Psychological impairments, cognitive deficits and negative illness perceptions were associated with reduced QOL in Cushing's syndrome. 25 Several randomized controlled trials suggest favourable QOL outcomes with pasireotide in patients achieving controlled urinary-free cortisol levels. 21, 26, 27 In one randomized control trial, CushingQOL scores were strongly correlated with the Becks Depression inventory score, suggesting psychological factors were influential in this change. 21 
| QOL in adrenal insufficiency
Quality of life is significantly reduced in patients with both primary and secondary adrenal insufficiency, irrespective of aetiology or type of glucocorticoid strategy.
| Glucocorticoid replacement
Bleicken et al 28 observed significantly reduced QOL in patients with adrenal insufficiency, irrespective of whether prednisolone or hydrocortisone was used for replacement. Reduced QOL was also observed in patients exceeding 30mg hydrocortisone per day, and thrice daily hydrocortisone was not shown to be superior to twice daily administration. 28 Plenadren is a once daily dual-release preparation of hydrocortisone, developed to maintain cortisol levels in a more physiological range, with favourable effects on body mass index, blood pressure and Hba1c. [29] [30] [31] [32] Compared to standard therapy, plenadren more closely replicates physiological cortisol profile with improvement in QOL in some observational studies 30, 32 and no change in others. 31 Continuous subcutaneous hydrocortisone infusion more closely replicates physiological cortisol release than standard oral Overall adherence to CONSORT-PRO based reporting guidelines across the studies (n = 117) hydrocortisone regimens, with improved QOL observed in some studies 33, 34 and no change in others. 35, 36 
| Mineralocorticoid replacement
There were no studies meeting inclusion criteria evaluating QOL and mineralocorticoid replacement strategies, and this is a potentially fertile area of research for the future.
| Androgen replacement
Arlt et al 37 insufficiency. 38 Another larger double-blind randomized controlled trial involving 108 women with primary adrenal insufficiency reported improved lean body mass and bone density with DHEA replacement, but no significant improvement in sexual function or QOL. 39 Miller et al 40 found improvements in mood, sexual function and QOL in 53 women with hypopituitarism receiving testosterone therapy 40 ; however, this finding has not been replicated elsewhere.
Overall, there is insufficient evidence to support routine androgen replacement in patients with adrenal insufficiency, although there may be a subset of women with severe androgen deficiency due to hypopituitarism who may benefit regarding mood and sexual function.
| QOL in congenital adrenal hyperplasia
Impaired QOL was observed in patients with CAH to a similar if not greater extent than in patients with adrenal insufficiency. 37 Adults with CAH remain shorter, more obese, with worse metabolic profile and QOL compared with the general population. 41 The CaHase study was the first to demonstrate a correlation between increased adiposity, insulin resistance and type of glucocorticoid replacement with impaired QOL in adults with CAH. 19 In this study, patients were grouped into prednisolone equivalent categories for data analysis, and QOL was observed to be worse in patients using prednisolone and dexamethasone compared with those taking hydrocortisone. 41 These data highlight the importance of early diagnosis and matters needing attention during long-term follow-up. Aspects of QOL affected by CAH include sexual debut, fertility and partnership. 42 Long-term follow-up studies suggest impairment in QOL of life correlates with the type of genital surgery in childhood and genetic mutation. 42 Both modified release glucocorticoid (Chronocort) and
continuous subcutaneous hydrocortisone infusion demonstrate closer approximation physiological cortisol secretion, favourable tolerability and effective control of androgen excess in patients with CAH in phase 2 studies. A small but statistically significant improvement in QOL was observed with continuous subcutaneous hydrocortisone infusion. However, the minimum important difference was not described. 42 No QOL benefit has been observed with Chronocort in patients with CAH. 
| QOL in primary aldosteronism
Impaired QOL in physical was reported by men and women with primary aldosteronism but more frequently reported in females, with untreated patients having the lowest QOL scores 44 A randomized controlled trial comparing CT scanning to adrenal vein sampling to localize pathology and direct management found no difference in QOL between these groups. 45 In patients undergoing unilateral adrenalectomy, improvement in blood pressure and biochemical parameters at 3 months were accompanied by an improvement in QOL. 46 In medically treated patients with bilateral adrenal hyperplasia, QOL improved at 6 months. However, the magnitude and speed of recovery were less than that previously observed in patients undergoing unilateral adrenalectomy. 18 Although the antihypertensive effect of spironolactone was much greater than that of eplerenone in patients with primary aldosteronism, the QOL scores in men favoured eplerenone due to breast discomfort from gynaecomastia with spironolactone. 47 The frequency of generalized anxiety disorder in patients with primary aldosteronism was found to be much higher than patients with essential hypertension or healthy controls (52% vs 17% vs 4%, respectively) in a study using interviews with a psychiatrist blinded to grouping. 
| QOL in patients presenting with adrenal mass
There were insufficient data to draw meaningful conclusions regarding QOL in patients presenting with adrenal mass. One observational study found impaired QOL and a higher level of physical fatigue in patients presenting with adrenal incidentaloma, and that surveillance programmes for adrenal incidentalomas were well tolerated despite some anxiety associated with the diagnosis. 49 Improved QOL scores were observed in one study of patients with subclinical Cushing's syndrome undergoing laparoscopic adrenalectomy compared with conservatively managed patients. 50 However, there is insufficient evidence to support routine surgery for this group of patients. Fassnacht et al 51 conducted a randomized control trial involving patients with inoperable adrenocortical cancers, using a validated cancer-specific QOL questionnaire to compare the effects of mitotane based chemotherapy regimens. This study showed that although the response rate and progression-free survival were significantly improved with EDP plus mitotane compared with streptozotocin plus mitotane as first-line therapy, the benefit did not improve overall survival or QOL. The addition of QOL evaluation here prevents the false assumption that treatment and improved progression survival would result in improved QOL.
| QOL in patients with chromaffin cell tumours
There were insufficient data to comment on QOL in patients with phaeochromocytoma. Quality of life data relating to patients with paraganglioma is scarce, limited to small cross-sectional studies or studies where patients were a subset of a larger cohort of patients.
Reduced QOL was found in a cross-sectional study of 176 patients with head-and-neck paraganglioma, with patients with paraganglioma, and SDH mutations found to have more avoidant coping style and lack of emotional expression. 52 Although not included in the review, a study of MEN2 patients following bilateral adrenalectomy reported reduced QOL with fatigue, worry and adherence to daily medications being the key concerns. 53 
| D ISCUSS I ON
This systematic review combines data across studies to describe QOL in patients with adrenal disease with more precision than is possible in a single study or using one approach to measurement.
A narrative synthesis was performed given the marked variation in study design, participants, interventions and reported outcomes.
The majority of QOL evaluations were performed in patients with Cushing's syndrome or adrenal insufficiency. However, QOL was reduced across the spectrum of adrenal disease. The processes by which this occurs are not well understood. We do not know if impaired QOL in adrenal disease results from a direct or indirect effect of exposure to hormone excess or deficiency state, the underlying disease process (benign or malignant), chronic illness, treatment side effects, psychological factors or a combination of the above.
Quality of life evaluation is increasingly being used to complement traditional end-points to evaluate the safety and effectiveness of interventions. 4 In this review, 50% of studies used QOL tools to evaluate interventions, most often to evaluate glucocorticoid replacement strategies. The study data show that improved biochemistry was not necessarily linked to improved QOL. This is in keeping with previous findings that physiological changes are usually inadequate substitutes for measuring QOL. For example, the SF-36 lacks questions relating to gonadal or sexual function which may be relevant to patients with adrenal disease. 15 Only one study demonstrated subtle changes in the disease-specific score not detected with generic instrument. 31 However were to be measured, failing to acknowledge limitations of the QOL measurement and potential for bias. These findings are consistent with previously reported inadequacies of trial reporting. 13 Reporting deficiencies limit the clinician's ability interpret QOL data and draw valid conclusions.
Current QOL measurements fail to account for the dynamic nature of QOL and underlying processes which influence responses over time. Stable scores do not necessarily reflect static QOL, as it may involve significant changes in values, priorities or conceptions of health to achieve the same QOL. 54 Current QOL tools do not account for "response shift," a change in the individuals own internal values or definition of QOL. 54 This is important as we cannot be sure if any change reflects the intervention itself or altered perception of QOL by that individual over time.
Limitations at the study level include the potential for publication bias with the inclusion of small, nonrandomized, observational trials. This review did not restrict study size to allow the inclusion of qualitative studies which are often smaller. In studies using multiple instruments, there is potential for bias from selective reporting leading to overestimation of effects. The use of generic instruments rather than disease-specific instruments may fail to detect subtle changes; however, disease-specific questionnaires are only available for patients with Cushing's syndrome or adrenal insufficiency.
Potential 
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